AU2012318279B2 - Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII - Google Patents

Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII Download PDF

Info

Publication number
AU2012318279B2
AU2012318279B2 AU2012318279A AU2012318279A AU2012318279B2 AU 2012318279 B2 AU2012318279 B2 AU 2012318279B2 AU 2012318279 A AU2012318279 A AU 2012318279A AU 2012318279 A AU2012318279 A AU 2012318279A AU 2012318279 B2 AU2012318279 B2 AU 2012318279B2
Authority
AU
Australia
Prior art keywords
factor viii
body weight
factor
sulfated glycosaminoglycan
sulfated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012318279A
Other languages
English (en)
Other versions
AU2012318279A1 (en
Inventor
Hubert Metzner
Sabine ZOLLNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2012318279A1 publication Critical patent/AU2012318279A1/en
Application granted granted Critical
Publication of AU2012318279B2 publication Critical patent/AU2012318279B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2012318279A 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII Ceased AU2012318279B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548606P 2011-10-18 2011-10-18
EP11185648 2011-10-18
EP11185648.0 2011-10-18
US61/548,606 2011-10-18
PCT/EP2012/070615 WO2013057167A1 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii

Publications (2)

Publication Number Publication Date
AU2012318279A1 AU2012318279A1 (en) 2013-05-02
AU2012318279B2 true AU2012318279B2 (en) 2015-06-04

Family

ID=48140372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012318279A Ceased AU2012318279B2 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII

Country Status (10)

Country Link
US (1) US9393289B2 (enExample)
EP (1) EP2768522B1 (enExample)
JP (1) JP6072810B2 (enExample)
KR (1) KR20140083036A (enExample)
CN (1) CN103889445A (enExample)
AU (1) AU2012318279B2 (enExample)
CA (1) CA2852397A1 (enExample)
DK (1) DK2768522T3 (enExample)
ES (1) ES2600081T3 (enExample)
WO (1) WO2013057167A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511123B2 (en) 2011-10-18 2016-12-06 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
JP6605593B2 (ja) 2014-06-06 2019-11-13 オクタファルマ・アーゲー 第ｖｉｉｉ因子およびフォン・ヴィルブランド因子ペプチドを含む製剤
EP3191524A4 (en) * 2014-09-12 2018-05-30 The Regents of The University of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
KR102698387B1 (ko) * 2015-02-06 2024-08-22 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108806A1 (en) * 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE69735421T2 (de) 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
AU1598200A (en) 1998-10-23 2000-05-15 Trustees Of The University Of Pennsylvania, The Systemic delivery of gene products via skin
US20040192599A1 (en) 2001-06-15 2004-09-30 Schuh Andre C Gene therapy for hemophilia a
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
BRPI0820271A2 (pt) * 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108806A1 (en) * 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Also Published As

Publication number Publication date
DK2768522T3 (en) 2016-11-14
EP2768522A1 (en) 2014-08-27
JP2014530246A (ja) 2014-11-17
CA2852397A1 (en) 2013-04-25
ES2600081T3 (es) 2017-02-07
AU2012318279A1 (en) 2013-05-02
US20140315815A1 (en) 2014-10-23
EP2768522B1 (en) 2016-07-27
US9393289B2 (en) 2016-07-19
KR20140083036A (ko) 2014-07-03
JP6072810B2 (ja) 2017-02-01
CN103889445A (zh) 2014-06-25
WO2013057167A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
CN103917554B (zh) 用于改善重构后纯化的因子viii的稳定性的方法
AU2012318303B2 (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
AU2012318279B2 (en) Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII
HK1197648B (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197648A (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197649B (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
KR20210134642A (ko) 재조합 vwf (rvwf)를 이용한 예방 치료 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired